



**Scientific Committee on Consumer Safety**  
**Combined meeting of the WG on Cosmetic Ingredients/ WG on Methodologies**  
**11 October 2012**

**Minutes**

**1. WELCOME AND APOLOGIES**

The Chairs of the working groups welcomed the participants and communicated the apologies received.

**2. ADOPTION OF THE AGENDA**

The draft agenda was adopted as proposed (see annex).

**3. DECLARATION OF INTEREST ON MATTERS OF THE AGENDA**

No new declarations of interest were made.

**WG on Cosmetic Ingredients**

**4. NEW REQUESTS**

A new mandate on DEGEE was presented to the WG and a rapporteur assigned for this opinion

**5. DRAFT OPINIONS**

Draft opinions on the following substances were presented by the rapporteurs and discussed by the Working Group. Changes were made to the drafts according to the discussion and the next steps were agreed to advance the assessments.

- 5.1 Dichloromethane
- 5.2 P81, Zinc pyrithione
- 5.3 Climbazole

## **WG on Methodologies**

### **6. UPDATES TO NOG**

The draft document was discussed in depth

### **7. PLANNING FOR WORKSHOP ON SAFETY ASSESSMENT OF SUBSTANCES WITH LOW ORAL BIOAVAILABILITY**

The WG decided on the final programme and the participants for a small targeted workshop on this topic

### **8. ANY OTHER BUSINESS**

The next combined meeting of the WGs on Cosmetic Ingredients and Methodologies will take place on 27 November 2012.

Annex



**EUROPEAN COMMISSION**  
HEALTH AND CONSUMERS DIRECTORATE-GENERAL

Public Health and Risk Assessment  
**Risk assessment**

**Scientific Committee on Consumer Safety (SCCS)**  
**WG on Cosmetic Ingredients**

**11 October 2012, meeting room BRE2 08/405**

**DRAFT AGENDA**

- 1. Welcome and apologies**
- 2. Adoption of the agenda**
- 3. Declaration of interest on matters on the agenda**

**Cosmetic Ingredients**

- 4. New requests**
- 5. Draft opinions on:**
  - 5.1. Dichloromethane**
  - 5.2. P81, Zinc pyrithione**
  - 5.3. Climbazole**

**Methodologies**

- 6. Updates to NoG**
- 7. Planning Workshop on dermal safety assessment of substances with low oral bioavailability**
- 8. Any Other Business**